- Home
- REPL vs XOMA Comparison
REPL vs XOMA Comparison
Compare REPL & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- XOMA
- Stock Information
- Founded
- REPL 2015
- XOMA 1981
- Country
- REPL United States
- XOMA United States
- Employees
- REPL N/A
- XOMA N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- REPL Health Care
- XOMA Health Care
- Exchange
- REPL Nasdaq
- XOMA Nasdaq
- Market Cap
- REPL 547.0M
- XOMA 457.6M
- IPO Year
- REPL 2018
- XOMA N/A
- Fundamental
- Price
- REPL $9.73
- XOMA $32.98
- Analyst Decision
- REPL Buy
- XOMA Strong Buy
- Analyst Count
- REPL 9
- XOMA 2
- Target Price
- REPL $10.88
- XOMA $69.50
- AVG Volume (30 Days)
- REPL 8.7M
- XOMA 46.3K
- Earning Date
- REPL 11-07-2025
- XOMA 11-05-2025
- Dividend Yield
- REPL N/A
- XOMA N/A
- EPS Growth
- REPL N/A
- XOMA N/A
- EPS
- REPL N/A
- XOMA N/A
- Revenue
- REPL N/A
- XOMA $44,952,000.00
- Revenue This Year
- REPL N/A
- XOMA $88.91
- Revenue Next Year
- REPL N/A
- XOMA $13.80
- P/E Ratio
- REPL N/A
- XOMA N/A
- Revenue Growth
- REPL N/A
- XOMA 194.98
- 52 Week Low
- REPL $2.68
- XOMA $18.35
- 52 Week High
- REPL $17.00
- XOMA $39.92
- Technical
- Relative Strength Index (RSI)
- REPL 76.27
- XOMA 39.11
- Support Level
- REPL $7.69
- XOMA $32.30
- Resistance Level
- REPL $10.85
- XOMA $35.71
- Average True Range (ATR)
- REPL 0.70
- XOMA 1.61
- MACD
- REPL 0.43
- XOMA -0.39
- Stochastic Oscillator
- REPL 89.86
- XOMA 11.94
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.